International Liver Cancer Association Annual Conference | Conference

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

September 19th 2023

The addition of toripalimab to standard-of-care sorafenib in the frontline setting demonstrated preliminary efficacy and tolerability in patients with unresectable hepatocellular carcinoma.

Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC

September 16th 2023

The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15th 2023

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.

Use of IO-Based Therapy Associated With Real-World OS Benefit in HCC

September 15th 2023

The use of an immuno-oncology regimen as systemic therapy was found to be an independent prognostic factor and was associated with improved long-term survival for patients with hepatocellular carcinoma, regardless of IO’s sequencing in the first and later lines of treatment.

Neoadjuvant Nivolumab/Ipilimumab Combo Elicits Responses, Safety in Resectable HCC

September 13th 2023

Neoadjuvant treatment with the combination of nivolumab and ipilimumab led to responses and was well tolerated in patients with resectable hepatocellular carcinoma.

Real-World Analysis Highlights US Treatment Patterns for Frontline Atezolizumab/Bevacizumab in HCC

September 12th 2023

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

Data for Second-Line or Later Ramucirumab Show Consistent Benefit in Advanced HCC

September 12th 2023

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

Second-line Ramucirumab Showcases Survival Benefits in HCC, Irrespective of Extrahepatic Spread

September 7th 2022

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

Black Patients With HCC, Those Living in High-Poverty Neighborhoods Have Higher Odds of Experiencing Treatment Delays

September 6th 2022

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

Sequential Combo of Regorafenib and Nivolumab Shows Manageable Safety in Sorafenib-Pretreated HCC

September 6th 2022

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC

September 7th 2021

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC

September 7th 2021

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Management of Toxicities Is Crucial to Immunotherapy Combination Use in HCC

September 7th 2021

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations

September 5th 2021

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

September 5th 2021

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.